--- title: "Sanofi sells its consumer health division, with Anhui Capital and PAI Partners among the bidders, with a valuation of up to 15 billion euros" description: "Sanofi plans to sell its consumer health division, with companies such as Advent International and PAI Partners participating in the bidding, valuing it as high as 15 billion euros. Sanofi's CEO state" type: "news" locale: "en" url: "https://longbridge.com/en/news/209123982.md" published_at: "2024-07-17T13:27:03.000Z" --- # Sanofi sells its consumer health division, with Anhui Capital and PAI Partners among the bidders, with a valuation of up to 15 billion euros > Sanofi plans to sell its consumer health division, with companies such as Advent International and PAI Partners participating in the bidding, valuing it as high as 15 billion euros. Sanofi's CEO stated that the company is reviewing separation plans and aims to complete the transaction in the fourth quarter of 2024. Sanofi hopes to create better long-term value by selling this business and may retain a minority stake. The company is also preparing for a potential IPO of this business According to the Zhītōng Finance and Economics APP, informed sources revealed that private equity firms Advent International and PAI Partners have submitted first-round bids for the consumer health division of French pharmaceutical company Sanofi (SNY.US). Clayton Dubilier & Rice has also made a preliminary acquisition offer for Sanofi's business, with some acquirers suggesting a valuation of up to 15 billion euros for the division. The business primarily sells over-the-counter products such as Phytoxil cough syrup and Icy Hot pain relief gel. A consortium composed of CVC Capital Partners Plc, Bain Capital, and Cinven did not submit bids before the deadline. Deliberations are still ongoing, and some bidders may choose to join forces later on. Informed sources added that more bidders may emerge. A representative of Sanofi stated that the company is reviewing potential separation options for the consumer health business, with the earliest completion of the transaction expected in the fourth quarter of 2024, and added that preparations are proceeding as planned. The representative said, "We are keeping all options open, including listing and selling, to maximize value for all stakeholders." In October last year, Sanofi announced plans to review all options for splitting the consumer health division, aiming to create better long-term value from cutting-edge therapies (especially in immunology or vaccines). Sources indicated that the pharmaceutical company is likely to retain a significant minority stake in the business after the sale, reducing the amount of capital bidders would need to invest. The company is also simultaneously advancing preparations for a potential IPO of the business. Sanofi CEO Paul Hudson stated earlier this month in an interview that the company is in negotiations with all interested parties, including private equity, and is also considering capital market options. "There is a lot of interest in this." PAI has always hoped to be the sole French bidder, a position that would put it in a favorable position to acquire the business. Jose Gonzalo, Executive Director of the French state investment company Bpifrance SACA, told reporters on July 4 that the company is also considering a potential investment in a Sanofi subsidiary and may collaborate with the winning bidder. The potential sale of the over-the-counter business could become one of the largest deals in Europe this year. Earlier this month, the left-wing coalition unexpectedly won the early parliamentary elections in France, preventing Marine Le Pen's far-right alliance from securing a majority, which also propelled the progress of the transaction. President Macron appointed a caretaker government on Tuesday, and negotiations for a new prime minister are still ongoing ### Related Stocks - [TBIO.US - Telesis Bio](https://longbridge.com/en/quote/TBIO.US.md) - [SNY.US - Sanofi](https://longbridge.com/en/quote/SNY.US.md) - [SNYNF.US - Sanofi](https://longbridge.com/en/quote/SNYNF.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 艾可菲｜10-K：2025 财年营收 60.75 亿美元超过预期 | | [Link](https://longbridge.com/en/news/276382538.md) | | 科帕特｜8-K：2026 财年 Q2 营收 11.22 亿美元不及预期 | | [Link](https://longbridge.com/en/news/276379291.md) | | 百汇生命 REIT 首获星展 7200 万元社会贷款 并拟发行 7000 万元绿色债券 \| 联合早报网 | 百汇生命产业信托（Parkway Life REIT）从星展银行获得 7200 万新元的社会贷款，并计划发行 7000 万新元的绿色债券。这是其首次获得社会贷款和发行绿色债券，符合新推出的可持续融资框架。信托管理公司表示，所获资金将用于再融 | [Link](https://longbridge.com/en/news/276454669.md) | | 全球财政刺激 “雷声大雨点小”？瑞银预计仅为 2026 年 GDP 增长贡献 8 个基点 | 瑞银研究指出，2026 年全球财政刺激实际影响接近中性，对 GDP 增长贡献仅约 8 个基点。尽管美、日、德等国法案热度高，但由于执行速度缓慢及新兴市场财政整固，实际力度远低于历史水平。全球经济仍需寻找内生动力，而非寄希望于政策红利。 | [Link](https://longbridge.com/en/news/276317126.md) | | 英格索兰｜10-K：2025 财年营收 76.51 亿美元超过预期 | | [Link](https://longbridge.com/en/news/276172246.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.